Is ropinirole appropriate for treating restless legs syndrome?

Ropinirole for Restless Legs Syndrome: Not Recommended as First-Line Therapy

Ropinirole should not be used as first-line treatment for restless legs syndrome due to a 7–10% annual risk of augmentation (iatrogenic worsening of symptoms), and the 2025 American Academy of Sleep Medicine guideline issues a conditional recommendation against its routine use. 1

Current Guideline Position on Ropinirole

The 2025 AASM guideline represents a major paradigm shift away from dopamine agonists including ropinirole, despite FDA approval and historical efficacy data. 1 This change prioritizes long-term safety over short-term symptom control. 1

• Ropinirole receives a conditional recommendation against standard use in both general RLS and ESRD-related RLS populations. 1
• The augmentation risk escalates with treatment duration, making long-term maintenance therapy particularly problematic. 1
• Augmentation manifests as: earlier daily symptom onset (afternoon instead of evening), shorter latency when immobile, spread to arms or trunk, and increased intensity prompting dose escalation. 1

FDA-Approved Efficacy vs. Guideline Safety Concerns

While ropinirole is FDA-approved for moderate-to-severe primary RLS 2, and three pivotal trials (RLS-1, RLS-2, RLS-3) demonstrated statistically significant improvements in IRLS scores and CGI-I response rates 2, the guideline now weighs augmentation risk more heavily than these short-term benefits. 1

• 12-week trial data: Mean IRLS score reductions of 11.2–13.5 points with ropinirole versus 8.0–9.8 points with placebo. 2
• CGI-I responder rates: 53.4–73.3% with ropinirole versus 39.6–56.5% with placebo. 2
• 36-week maintenance data: Relapse rate of 32.6% with ropinirole versus 57.8% with placebo after discontinuation. 2
• However: These efficacy data do not outweigh the 7–10% annual augmentation risk documented in longer-term observational studies. 1

Recommended First-Line Alternatives

Gabapentinoids receive strong recommendations (moderate certainty) as first-line therapy:

• Gabapentin enacarbil 1
• Gabapentin 1
• Pregabalin 1

Iron repletion is mandatory before initiating any pharmacotherapy:

• IV ferric carboxymaltose 1000 mg when ferritin ≤100 ng/mL or transferrin saturation <20% (strong recommendation). 1
• Oral ferrous sulfate 325–650 mg daily or every other day (conditional recommendation). 1

Limited Role for Ropinirole: Short-Term Use Only

Ropinirole may be considered only for short-term therapy when:

• Patients explicitly prioritize rapid symptom relief over long-term safety and accept augmentation risk. 1
• Gabapentinoids have failed or are not tolerated. 1
• The patient is not a candidate for opioid therapy. 1
• A plan exists to transition to first-line therapy within weeks to months. 1

Typical dosing (per FDA label): Start 0.25 mg once daily 1–3 hours before bedtime; titrate over 7 weeks to maximum 4 mg once daily based on response and tolerability. 2

Critical Management Pitfalls

• Do not start ropinirole before correcting iron deficiency—this exposes patients to augmentation risk while a safer, disease-modifying intervention is available. 1
• Do not escalate the ropinirole dose in response to worsening symptoms—this likely reflects augmentation rather than tolerance and will exacerbate the problem. 1
• Do not use ropinirole for long-term maintenance—augmentation risk escalates with duration of use. 1
• If augmentation is detected, discontinue ropinirole immediately and switch to a gabapentinoid or low-dose opioid; never increase the dose. 1

Second-Line Options for Refractory RLS

If gabapentinoids fail after 4–6 weeks of optimized therapy:

• Extended-release oxycodone (5–10 mg daily) or other opioids are preferred over dopamine agonists (conditional recommendation, moderate certainty). 1
• Bilateral high-frequency peroneal nerve stimulation (conditional recommendation, moderate certainty). 1

Special Consideration: ESRD Patients

In end-stage renal disease, ropinirole is explicitly contraindicated along with pramipexole, cabergoline, bupropion, carbamazepine, clonazepam, and valproic acid. 1 The ESRD-specific algorithm prioritizes:

1. Renally-adjusted gabapentin (100–300 mg post-dialysis). 1
2. IV iron sucrose when ferritin <200 ng/mL and transferrin saturation <20%. 1
3. Vitamin C supplementation as adjunct. 1

Treatment Algorithm

1. Measure ferritin and transferrin saturation after 24-hour iron avoidance. 1
2. Initiate iron repletion if ferritin ≤100 ng/mL or TSAT <20%. 1
3. Discontinue RLS-exacerbating medications (serotonergic antidepressants, dopamine antagonists, antihistamines). 1
4. Start a gabapentinoid (strong recommendation). 1
5. If inadequate response after 4–6 weeks, add or switch to extended-release oxycodone rather than ropinirole. 1
6. Reserve ropinirole only for short-term use when patients explicitly accept augmentation risk. 1